U.S. FDA Continues Retrospective Safety Review of Mifepristone

The U.S. Food and Drug Administration is advancing a retrospective safety study concerning the abortion medication mifepristone. This analysis, which involves a large number of cases, could potentially influence future access to the drug. Interim findings from this ongoing review are anticipated by July.